These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 18023335)

  • 1. Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients.
    Lötvall J; Ankerst J
    Respir Med; 2008 Mar; 102(3):449-56. PubMed ID: 18023335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.
    Bjermer L; Rosenborg J; Bengtsson T; Lötvall J
    Ther Adv Respir Dis; 2013 Oct; 7(5):264-71. PubMed ID: 23907810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients.
    Rosenborg J; Larsson P; Rott Z; Böcskei C; Poczi M; Juhász G
    Eur J Clin Pharmacol; 2002 Jul; 58(4):S61-7. PubMed ID: 12214580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
    Busse W; Levine B; Andriano K; Lavecchia C; Yegen U
    Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cumulative high doses of inhaled formoterol have less systemic effects in asthmatic children 6-11 years-old than cumulative high doses of inhaled terbutaline.
    Kaae R; Agertoft L; Pedersen S; Nordvall SL; Pedroletti C; Bengtsson T; Johannes-Hellberg I; Rosenborg J
    Br J Clin Pharmacol; 2004 Oct; 58(4):411-8. PubMed ID: 15373934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
    Aziz I; Hall IP; McFarlane LC; Lipworth BJ
    J Allergy Clin Immunol; 1998 Mar; 101(3):337-41. PubMed ID: 9525449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bronchodilation and bronchoprotection in asthmatic preschool children from formoterol administered by mechanically actuated dry-powder inhaler and spacer.
    Nielsen KG; Bisgaard H
    Am J Respir Crit Care Med; 2001 Jul; 164(2):256-9. PubMed ID: 11463597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease.
    Rosenkranz B; Rouzier R; Kruse M; Dobson C; Ayre G; Horowitz A; Fitoussi S
    Respir Med; 2006 Apr; 100(4):666-72. PubMed ID: 16303295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial.
    Haney S; Hancox RJ
    Respir Res; 2005 Sep; 6(1):107. PubMed ID: 16168062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The duration of action of inhaled formoterol dry powder.
    Quebe-Fehling E; Brambilla R; Bromly CL; Fishwick K; Walters EH; Hendrick DJ
    Br J Clin Pract; 1996 Dec; 50(8):446-9. PubMed ID: 9039716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma.
    Kruse M; Rosenkranz B; Dobson C; Ayre G; Horowitz A
    Pulm Pharmacol Ther; 2005; 18(3):229-34. PubMed ID: 15707858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthma.
    LaForce C; Prenner BM; Andriano K; Lavecchia C; Yegen U
    J Asthma; 2005 Mar; 42(2):101-6. PubMed ID: 15871441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A; Szalai Z; Pullerits T; Radeczky E
    Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol.
    Goldkorn A; Diotto P; Burgess C; Weatherall M; Holt S; Beasley R; Siebers R
    Respirology; 2004 Mar; 9(1):102-8. PubMed ID: 14982610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bronchial asthma treated with long-acting beta 2 agonist. Comparison between formoterol (12 mu/g) inhaled twice daily and salbutamol (200 mu/g) inhaled 4 times daily].
    Sprogøe-Jakobsen U; Viktrup L; Davidsen O; Viskum K
    Ugeskr Laeger; 1992 Nov; 154(47):3325-8. PubMed ID: 1361083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
    Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
    Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formoterol Turbuhaler as reliever medication in patients with acute asthma.
    Rubinfeld AR; Scicchitano R; Hunt A; Thompson PJ; Van Nooten A; Selroos O
    Eur Respir J; 2006 Apr; 27(4):735-41. PubMed ID: 16455838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinically equivalent bronchodilatation achieved with formoterol delivered via Easyhaler and Aerolizer.
    Dubakiene R; Nargela R; Sakalauskas R; Vahteristo M; Silvasti M; Lähelmä S
    Respiration; 2006; 73(4):441-8. PubMed ID: 16432294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Onset of effect of budesonide and formoterol administered via one pressurized metered-dose inhaler in patients with asthma previously treated with inhaled corticosteroids.
    Kaiser H; Parasuraman B; Boggs R; Miller CJ; Leidy NK; O'Dowd L
    Ann Allergy Asthma Immunol; 2008 Sep; 101(3):295-303. PubMed ID: 18814453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial.
    Pleskow W; LaForce CF; Yegen U; Matos D; Della Cioppa G
    J Asthma; 2003; 40(5):505-14. PubMed ID: 14529100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.